Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation

Pain Medicine

Volumn 11, Issue 1, 2010, Pages 81-91

  Butler, Stephen F ^a   Black, Ryan ^a   Grimes Serrano, Jill M ^a   Folensbee, Lesley ^a   Chang, Alan ^a   Katz, Nathaniel ^b  

^a INFLEXXION INC   (United States)

^b Analgesic Research   (United States)

Author keywords

Abuse; Attractiveness; Prescription opioids

Indexed keywords

HYDROCODONE BITARTRATE PLUS PARACETAMOL; OXYCODONE; PENTAZOCINE; PERCOCET; RECREATIONAL DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG ABUSE PATTERN; DRUG FORMULATION; DRUG PREFERENCE; FEMALE; HUMAN; INJECTION; MALE; NARCOTIC DEPENDENCE; OPIOID ATTRACTIVENESS TECHNOLOGY SCALING; PRESCRIPTION; RATING SCALE; SWALLOWING;

EID: 74049118066     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00737.x     Document Type: Article

References (29)

1. Federal report shows new nonmedical users of prescription pain relievers outnumbered new marijuana users between 2002 and 2004. 2006, http://www.samhsa.gov/newsroom/advisories/061102misuse5701.aspx, Substance Abuse and Mental Health Services Administration, Rockville, MD, Available at: (accessed June 22, 2007
2. Johnston LD, O'Malley PM, Bachman JG, Schulenburg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings 2008, Bethesda, MD, National Institutes on Drug Abuse, National Institutes of Health, Contract No: NIH Publication No. 08-6418
3. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004, 28(2):176-88.
4. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 2006, 81(2):103-7.
5. Roset PN, Farre M, de la Torre R. Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. Drug Alcohol Depend 2001, 64(3):285-98.
6. Marsch LA, Bickel WK, Badger GJ. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 2001, 299(3):1056-65.
7. Butler SF, Fernandez KC, Chang A, Benoit C, Katz N. A measurement of prescription opioid attractiveness: Pain Med. Submitted for Publication
8. Butler SF, Benoit C, Budman SH. Development and validation of an Opioid Attractiveness Scale: A novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006, 3:5.
9. Comer SD, Ashworth JB, Foltin RW. The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 2008, 96(1-2):1-15.
10. Katz NP, Adams EH, Chilcoat H. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007, 23(8):648-60.
11. Katz N. Abuse-deterrent opioid formulations: Are they a pipe dream? Curr Rheumatol Rep 2008, 10(1):11-18.
12. Wright CT, Kramer ED, Zalman MA, Smith MY, Haddox JD. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend 2006, 83(1):S68-76. suppl
13. Webster LR. PTI-821: Sustained-release oxycodone using gel-cap technology. Expert Opin Investig Drugs 2007, 16(3):359-66.
14. Webster LR, Butera PG, Moran LV. Oxytrex minimizes physical dependence while providing effective analgesia: A randomized controlled trial in low back pain. J Pain 2006, 7(12):937-46.
15. Mansbach RS, Moore RA. Formulation considerations for the development of medications with abuse potential. Drug Alcohol Depend 2006, 83(1):S15-22. suppl
16. Butler SF, Budman SH, Licari A. National addictions vigilance intervention and prevention program (NAVIPPRO™): A real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008, 17(12):1142-54.
17. Butler SF, Budman SH, Goldman RJ. Initial validation of a computer-administered Addiction Severity Index: The ASI-MV. Psychol Addict Behav 2001, 15(1):4-12.
18. Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess 1994, 6:284-90.
19. Anastasi A, Urbaina S. Psychological Testing 1997, 7th, edition, Upper Saddle River, NJ, Prentice Hall Inc
20. Bickel R. Multilevel Analysis for Applied Research: It's Just Regression 2007, New York, Guilford Press
21. Snijders T, Bosker R. Multilevel Analysis 1999, Thousand Oaks, CA, Sage
22. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, 2nd, edition, New York, Lawrence Erlbaum
23. Chow S-C, Shao J, Wang H. Sample Size Calculations in Clinical Research 2008, 2nd, edition, New York, Chapman & Hall/CRC
24. National Prevalence Data with Correlates of Substance Abuse: SAMHSA's National Survery on Drug Use & Health 2006, SAMHSA, Rockville, MD, Office of Applied Studies (OAS); Department of Health and Human Services (DHHS)
25. Zacny JP, Gutierrez S. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug Alcohol Depend 2009, 101(1-2):107-14.
26. Zacny JP, Gutierrez S. Subjective, psychomotor, and physiological effects profile of hydrocodone/acetaminophen and oxycodone/acetaminophen combination products. Pain Med 2008, 9(4):433-43.
27. Zacny JP, Lichtor SA. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology (Berl) 2008, 196(1):105-16.
28. Zacny JP, Goldman RE. Characterizing the subjective, psychomotor, and physiological effects of oral propoxyphene in non-drug-abusing volunteers. Drug Alcohol Depend 2004, 73(2):133-40.
29. Zacny JP, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology (Berl) 2003, 170(3):242-54.